Skip to main content

A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Research Question:
Does the drug Litifilimab reduce disease in people with lupus?

Basic Study Information

You may be eligible to take part in the study because you have an autoimmune disease known as “lupus.” In autoimmune diseases, the immune system sees the body’s own tissues as “foreign” and attacks itself, resulting in inflammation. Systemic lupus erythematosus, otherwise known as SLE, can affect many different parts of the body but frequently involves the joints, skin, kidneys, blood cells, and mucus membranes (the lining of the mouth, nose, throat, stomach, and intestines), which can result in symptoms such as swollen joints, rash, foamy urine, changes in red or white blood cells, and oral ulcers, among others. Only people who have been diagnosed with SLE for at least 6 months can take part in the study. The purpose of the study is to investigate if the investigational study drug litifilimab (BIIB059) can reduce disease activity and inflammation in people with active SLE compared to a placebo.

Location: University of Rochester Medical Center
Study Reference #: STUDY00006992

Lead Researcher (Principal Investigator)

Lead Researcher:  Jennifer Anolik, MD, PhD

Study Contact Information

Study Coordinator: Maria Allen
Phone: (585) 275-1632

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search